CSL Limited responds to FTC announcement

CSL Limited responds to FTC announcement

Melbourne, Australia — 28/05/2009

CSL Limited (ASX: CSL) today was informed that the US Federal Trade Commission (“FTC”) will file a complaint in the US Federal District Court to challenge CSL’s proposed acquisition of Talecris Biotherapeutics.

Dr. Brian McNamee, CEO and Managing Director of CSL Limited, said, “We strongly disagree with the FTC’s decision to challenge the deal. CSL intends to vigorously oppose the FTC’s actions. The FTC has failed to recognize that this combination is pro-competitive, provides significant efficiencies that will improve the supply of biotherapies, and is beneficial to the patient community. The Commission failed to take into account the substantial remedies that were offered by CSL which addressed their concerns especially in relation to plasma supply, Alpha-1 and RhoD.”

Download this release:
PDF icon CSL Limited responds to FTC announcement (0.89 MB)

Analyst Briefing:
Listen to the recording made during the analyst briefing

Media Contacts: 
Dr Rachel David
  Director, Public Affairs
  CSL Limited
  Telephone: +613 9389 1821
  Email: rachel.david@csl.com.au

Tim Duncan
  Hinton & Associates
  Telephone: +613 9600-1979
  Email: tduncan@hintons.com.au

United States 
Stan Neve & Robin Gilliland
  Brunswick Group
  Telephone: +1 212 333 3810
  Email: sneve@brunswickgroup.com

Investor Contact: 
Mark Dehring
  Head of Investor Relations
  CSL Limited
  Telephone: +613 9389 2818
  Email: mark.dehring@csl.com.au

© 2017 CSL Limited